|
|
Volumn 13, Issue , 2013, Pages
|
|
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC ANTIMETABOLITE;
B RAF KINASE;
BETA CATENIN;
BRAF PROTEIN, HUMAN;
CD8 ANTIGEN;
FLUOROURACIL;
PROTEIN P53;
THYMIDYLATE SYNTHASE;
TUMOR MARKER;
ADENOCARCINOMA;
ADJUVANT CHEMOTHERAPY;
AGED;
ARTICLE;
CANCER STAGING;
COLON RESECTION;
COLON TUMOR;
CPG ISLAND;
DISEASE MANAGEMENT;
FEMALE;
FOLLOW UP;
GENETICS;
HUMAN;
MALE;
METABOLISM;
MIDDLE AGED;
MISMATCH REPAIR;
MORTALITY;
MULTIMODALITY CANCER THERAPY;
MUTATION;
PATHOLOGY;
RETROSPECTIVE STUDY;
SURVIVAL RATE;
ADENOCARCINOMA;
AGED;
ANTIGENS, CD8;
ANTIMETABOLITES, ANTINEOPLASTIC;
BETA CATENIN;
CHEMOTHERAPY, ADJUVANT;
COLECTOMY;
COLONIC NEOPLASMS;
COMBINED MODALITY THERAPY;
CPG ISLANDS;
DISEASE MANAGEMENT;
DNA MISMATCH REPAIR;
FEMALE;
FLUOROURACIL;
FOLLOW-UP STUDIES;
HUMANS;
MALE;
MIDDLE AGED;
MUTATION;
NEOPLASM STAGING;
PROTO-ONCOGENE PROTEINS B-RAF;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
THYMIDYLATE SYNTHASE;
TUMOR MARKERS, BIOLOGICAL;
TUMOR SUPPRESSOR PROTEIN P53;
|
|
EID: 84874250326
PISSN: None
EISSN: 1471230X
Source Type: None
DOI: 10.1186/1471-230X-13-36 Document Type: Article |
|
Times cited : (51)
|
|
References (0)
|
